MedPath

Imbruvica

Brand Name: Imbruvica

Generic Name: Ibrutinib

Active
Registration Number

DR-XY48674

Dosage Form

Film-Coated Tablet

Issuance Date

September 28, 2023

Expiry Date

March 30, 2028

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength420 mg
PackagingPVC/PCTFE/Alu Blister Pack x 14’s

Classification

C
Classification
Prescription Drug (RX)
P
Pharmacologic
Antineoplastic Agent (Protein Kinase Inhibitor)
A
Application
Monitored Release (Correction)
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

IbrutinibActive
Monograph: Ibrutinib

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform